PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 9/3010% below fair value
$16.94+1.18 (+7.49%)
Close on Nov 18, 2026Market cap $2.35BP/E –Yield 6.85%
Perrigo revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Perrigo's revenue for the twelve months ending Jun 27, 2026 was $4.14B, down 4.2% year over year. For fiscal 2025 it was $4.25B, down 2.8% from the year before. Over ten years it grew 0.8% a year on average. The highest annual figure on record is $4.95B in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.25B | -2.8% |
| FY2024 | Dec 31, 2024 | $4.37B | -6.1% |
| FY2023 | Dec 31, 2023 | $4.66B | +4.6% |
| FY2022 | Dec 31, 2022 | $4.45B | +7.6% |
| FY2021 | Dec 31, 2021 | $4.14B | +1.2% |
| FY2020 | Dec 31, 2020 | $4.09B | +5.6% |
| FY2019 | Dec 31, 2019 | $3.87B | -18.2% |
| FY2018 | Dec 31, 2018 | $4.73B | -4.3% |
| FY2017 | Dec 31, 2017 | $4.95B | +17.0% |
| FY2015 | Jun 27, 2015 | $4.23B | +8.0% |
| FY2014 | Jun 28, 2014 | $3.91B | +489162.5% |
| FY2013 | Jun 29, 2013 | $800.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $1.02B | -3.2% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $969.20M | -7.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $1.11B | -2.5% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $1.04B | -4.1% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $1.06B | -0.9% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $1.04B | -3.5% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $1.14B | -1.6% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $1.09B | -3.2% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $1.07B | -10.7% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $1.08B | -8.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.16B | +0.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $1.12B | +2.1% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $1.19B | +6.4% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $1.18B | +10.0% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $1.16B | +4.6% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $1.10B | +5.5% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $1.12B | +14.3% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $1.07B | +6.4% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $1.10B | -14.3% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $1.04B | +4.0% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $981.10M | +3.4% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $1.01B | -6.8% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $1.29B | -2.5% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $1.00B | -15.8% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $948.80M | -17.4% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $1.08B | -7.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $1.32B | +10.7% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $1.19B | +5.1% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $1.15B | -3.2% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $1.17B | -3.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $1.20B | -6.8% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $1.13B | -8.0% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $1.19B | -4.2% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $1.22B | +1.9% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $1.28B | -9.3% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $1.23B | +27.3% |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $1.24B | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $1.19B | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $1.42B | – |
| Q3 FY2015CQ1 2015 | Mar 28, 2015 | $967.20M | – |
See a number that looks wrong?